Companies › BioAtla
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BA3182 Conditionally active bispecific T-cell engager (BiTE) antibody targeting EpCAM and CD3 | EPCAM, CD3E | Phase 1 | Advanced Adenocarcinoma | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05808634 | BA3182 | Phase 1 | Advanced Adenocarcinoma | Oncology | Sep 2028 |
Cash of $2m on 2026-06-30; operating cash outflow about $12m a year; runway about 2 months at that burn, to Aug 2026
Press releases filed as 8-K in the last year:
Johnson & Johnson (Janssen) Wuhan YZY Biopharma Regeneron Pharmaceuticals Amgen Roche AstraZeneca AcadeMab Biomedical Mirador Therapeutics Tiziana Life Sciences Sanofi
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.